StreetInsider.com News Articles

DiagnosTear Announces Positive Final Results from Clinical Study Demonstrating Strong Diagnostic Performance of TeaRx(TM) Red Eye for Detecting Total Tear IgE as a Biomarker for Allergic conjunctiviti

Thu, 10 Sep 2026 08:30:00 -0400

Final study results demonstrate 89% sensitivity, 83.3% specificity compared with quantitative ELISA reference testing for IgE detection.

Vancouver, British Columbia--(Newsfile Corp. - September 10, 2026) - DiagnosTear Technologies Inc. (CSE: DTR) (FSE: X8F) ("DiagnosTear" or the "Company"), an innovator in point-of-care ocular diagnostics, is pleased to announce positive final results from its clinical study conducted with AlyaTec for TeaRx™ Red Eye further to the Company's press releases dated December 2, 2025, February 26, 2026, and July 9, 2026.

The final results were obtained and analysed from 93 tear samples originating from 31 subjects tested before and after ocular provocation with feline allergen.

DiagnosTear Announces Positive Final Results from Clinical Study Demonstrating Strong Diagnostic Performance of TeaRx(TM) Red Eye for Detecting Total Tear IgE as a Biomarker for Allergic conjunctiviti

Thu, 10 Sep 2026 08:30:00 -0400

Final study results demonstrate 89% sensitivity, 83.3% specificity compared with quantitative ELISA reference testing for IgE detection.

The final results were obtained and analysed from 93 tear samples originating from 31 subjects tested before and after ocular provocation with feline allergen.

DiagnosTear Technologies Announces FDA Pre-Submission for TeaRx(TM) Red Eye Diagnostic Test

Thu, 03 Sep 2026 07:00:00 -0400

Vancouver, British Columbia--(Newsfile Corp. - September 3, 2026) - DiagnosTear Technologies Inc. (CSE: DTR) (FSE: X8F) ("DiagnosTear" or the "Company"), a developer of innovative point-of-care eye diagnostic solutions, is pleased to announce the submission of a pre-submission request to the U.S. Food and Drug Administration ("FDA") for its TeaRx™ Red Eye diagnostic test (the "Pre-Submission").

The Pre-Submission represents an important regulatory milestone in the Company's U.S. development strategy for TeaRx™ Red Eye. DiagnosTear is seeking FDA's input on the product's regulatory pathway and data development plan.

TeaRx™ Red Eye is being developed as a rapid, point-of-care test to aid healthcare professionals

DiagnosTear Technologies Announces FDA Pre-Submission for TeaRx(TM) Red Eye Diagnostic Test

Thu, 03 Sep 2026 07:00:00 -0400

TeaRx™ Red Eye is being developed as a rapid, point-of-care test to aid healthcare professionals

DiagnosTear plans private placement raising up to C$1.4M

Mon, 31 Aug 2026 07:01:17 -0400

DiagnosTear Technologies Inc. (CSE: DTR) (FSE: X8F) announced a non-brokered private placement of up to 2,800,000 units at C$0.50 per unit, seeking gross proceeds of up to C$1,400,000.

Each unit consists of one common share and one warrant exercisable at C$1.00 per share for 12 months from the closing date. BioLight Life Sciences Ltd., the parent company of DiagnosTear, and Elcam Medical Ltd. are each expected to participate for up to one-third of the total offering.

The company said proceeds will be used for working capital and general corporate purposes. No finder's fees will be paid in connection with the offering.

Certain insiders

DiagnosTear Technologies Inc. Announces Private Placement of Units

Mon, 31 Aug 2026 07:00:00 -0400

Vancouver, British Columbia--(Newsfile Corp. - August 31, 2026) - DiagnosTear Technologies Inc. (CSE: DTR) (FSE: X8F) ("DiagnosTear" or the "Company") is pleased to announce it will be proceeding with a non-brokered private placement of up to 2,800,000 units ("Units") at a price of C$0.50 per Unit for aggregate gross proceeds of up to C$1,400,000 (the "Offering"). The Company expects BioLight Life Sciences Ltd., parent company of DiagnosTear, and Elcam Medical Ltd. to each participate for up to one-third of the total Offering.

Each Unit will consist of one common share of the Company (a "Common Share") and one common

DiagnosTear Technologies Inc. Announces Private Placement of Units

Mon, 31 Aug 2026 07:00:00 -0400

Each Unit will consist of one common share of the Company (a "Common Share") and one common

Form F-6EF DATELINE RESOURCES LTD/A Filed by: Deutsche Bank Trust Co Americas/ ADR Group

Tue, 14 Apr 2026 14:20:00 -0400

si-local-file:///var/storage/secattach/20260414/26311396.html

Form F-6EF DATELINE RESOURCES LTD/A Filed by: Deutsche Bank Trust Co Americas/ ADR Group

Tue, 14 Apr 2026 14:20:00 -0400

si-local-file:///var/storage/secattach/20260414/26311396.html

Form F-6EF DATELINE RESOURCES LTD/A Filed by: Deutsche Bank Trust Co Americas/ ADR Group

Tue, 14 Apr 2026 14:20:00 -0400

si-local-file:///var/storage/secattach/20260414/26311396.html

Antimony Market Becoming a Billion Dollar Revenue Opportunity with Significantly Usage & Growth Expected

Mon, 08 Dec 2025 09:25:00 -0400